In addition to multilateral cooperations within European projects, Genopole® is involved in a number of bilateral cooperations, with:
The Quebec Biotechnology Innovation Centre (“Centre québécois d’innovation en biotechnologie”, CQIB), November 2001: a collaboration agreement with the Montreal Metropolitan Area’s biotech and healthcare company incubator. This agreement promotes scientific and business relationships between the start-ups in Evry and those from the Montreal Metropolitan Area and has enabled both organizations to raise their respective profiles.
The Biotech City (Montreal Metropolitan Area), March 2006: a cooperation agreement which opens up new channels for scientific and commercial dialogue between Quebec and France in the biotech sector.
Saudi Arabian universities, March 25, 2008: as part of the umbrella agreement signed by the French President while in Saudi Arabia in January 2008 and under the terms of one of the agreements signed during a visit to France by Dr Khaled Bin Mohamed Al Anqari (the Saudi Minister for Higher Education), Genopole® will develop a number of joint projects with King Saud University in Riyadh and King Abdulaziz University in Jeddah - particularly in the fields of stem cells and medicinal chemistry. Genopole® will also help develop a technology park on the King Saoud University campus.
LifeScience Cluster Krakov (Poland), July 4, 2008: a memorandum of understanding formalized the two organization’s intention to cooperate in the field of life sciences in general and biotech in particular. Genopole® will advise the newly created Polish cluster for an initial one-year period (notably on creating a seed fund).
Biolake Wuhan - Hubei province (China), Nov 9, 2010: The framework agreement sets out the basis for commercial exchanges of knowledge and services: technology transfer, staff training and the provision of business services for French biotech companies seeking to establish themselves in China and vice versa. Biolake Wuhan will cover an extremely large area and is due to be completed within two years. In order to achieve the mandatory international levels of competitiveness, the Chinese biocluster will have to leverage its significant human and financial resources to create high-level infrastructures and facilities. This is the focus of the agreement with Genopole - the incorporation of cutting-edge technologies developed on the Evry biopark.